ArticleClinical and experimental nephrology2026
Effects of processed low-protein brown rice on patients with chronic kidney disease.
Article in Clinical and experimental nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Does the reported eGFR decline reflect a previously described cohort? Comment on "Effects of processed low-protein brown rice on patients with chronic kidney disease".Clinical and experimental nephrology · 2026Article
- Low-protein brown rice in CKD: dietary substitution or microbiome signal?Clinical and experimental nephrology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlterations in gut microbiota are prevalent in patients with chronic kidney disease (CKD) and are associated with pathogenic phenotypes, including the progression of kidney damage and defecation conditions. We developed a fermented low-protein brown rice (LPBR), a whole grain unpolished rice, and examined its effects on renal function, defecation condition, and gut microbiota composition in CKD patients.
methodsIn this 3-month, single-arm study, 30 outpatients with stage 3 - 4 CKD were recruited and received a dietary intervention with LPBR. Changes in the defecation condition were evaluated using the Constipation Scoring System (CSS) and the Bristol Stool Form Scale. Alterations in urinary protein excretion and estimated glomerular filtration rate (eGFR) as well as stool condition were assessed as primary outcomes.
resultsAmong the 29 participants with CKD, intervention with LPBR led to a significant improvement in CSS scores (P = 0.023), a reduction in urinary protein excretion (P = 0.050), and a decrease in eGFR levels (P = 0.044). Fecal acetic acid increased (P = 0.024) and the abundance of Bifidobacterium longum in the gut microbiota increased (P = 0.094). Changes in Bifidobacterium longum were positively associated with alterations in fecal acetic acid levels and CCS scores. Additionally, changes in fecal acetic acid were positively associated with changes in eGFR and Bristol stool scores.
conclusionThe trend toward increased Bifidobacterium longum abundance and elevated acetic acid production with LPBR intake may contribute to the attenuation of CKD complications. Our findings suggest that LPBR intervention may offer beneficial effects for CKD patients.
Indexed as
Identifiers
42189410What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.